Ataca, P. Et Al. 2014. Favorable Treatment Alternative for Primary Central Nervous System Lymphoma: Combined Chemotherapy Regimen Consisting of High-Dose Methotrexate, Rituximab and Cytosine-Arabinoside. BLOOD , vol.124, no.21 , 5462.

Ataca, P., Toprak, S. K., Atilla, E., Topcuoglu, P., Kurt Yuksel, M., Kaygusuz, G., ... Kuzu, I.(2014). Favorable Treatment Alternative for Primary Central Nervous System Lymphoma: Combined Chemotherapy Regimen Consisting of High-Dose Methotrexate, Rituximab and Cytosine-Arabinoside. BLOOD , vol.124, no.21, 5462.

Ataca, Pinar Et Al. "Favorable Treatment Alternative for Primary Central Nervous System Lymphoma: Combined Chemotherapy Regimen Consisting of High-Dose Methotrexate, Rituximab and Cytosine-Arabinoside," BLOOD , vol.124, no.21, 5462, 2014

Ataca, Pinar Et Al. "Favorable Treatment Alternative for Primary Central Nervous System Lymphoma: Combined Chemotherapy Regimen Consisting of High-Dose Methotrexate, Rituximab and Cytosine-Arabinoside." BLOOD , vol.124, no.21, pp.5462, 2014

Ataca, P. Et Al. (2014) . "Favorable Treatment Alternative for Primary Central Nervous System Lymphoma: Combined Chemotherapy Regimen Consisting of High-Dose Methotrexate, Rituximab and Cytosine-Arabinoside." BLOOD , vol.124, no.21, p.5462.

@article{article, author={Pinar Ataca Et Al. }, title={Favorable Treatment Alternative for Primary Central Nervous System Lymphoma: Combined Chemotherapy Regimen Consisting of High-Dose Methotrexate, Rituximab and Cytosine-Arabinoside}, journal={BLOOD}, year=2014, pages={5462} }